An experimental investigation revealed that GPR55 promotes the proliferation and growth of pancreatic cancer tumors through MAPK signaling, and inhibition of GPR55 increases the therapeutic effects of gemcitabine [13]. This evidence concerns the gene GPR55 and pancreatic neoplasm.